- À propos de Gimv
- Focus d'investissement
- Notre équipe & Bureaux
Ablynx announces Q1 2012 business update
GHENT, Belgium, 16th May 2012 - Ablynx [Euronext Brussels: ABLX], the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies® for the treatment of serious life-threatening diseases, today announced its business update for the three-month period ending 31st March 2012.